Global prevalence and molecular characterization of extended-spectrum β-lactamase producing- Escherichia coli in dogs and cats - A scoping review and meta-analysis - PubMed (original) (raw)

Review

Global prevalence and molecular characterization of extended-spectrum β-lactamase producing- Escherichia coli in dogs and cats - A scoping review and meta-analysis

Marília Salgado-Caxito et al. One Health. 2021.

Abstract

Antimicrobial resistance (AMR) represents a major threat to human and animal health. Part of the AMR dimension is the circulation of extended-spectrum β-lactamases producing-Escherichia coli (ESBL-E. coli), which is now commonly reported among companion animals. However, the global perspective of the prevalence and population structure of ESBL-E. coli circulating in dogs and cats has not been estimated limiting our understanding of their role in the dissemination of ESBL-E. coli. The aim of this study was to compare the prevalence of ESBL-E. coli between dogs and cats and across countries through meta-analysis. We also performed a scoping review to summarize the current knowledge on ESBL genes and E. coli clones circulating among companion animals. A total of 128 studies published in PubMed, Web of Science, and Scopus up to April 2020 were selected and contained information on prevalence and/or molecular characterization of ESBL genes and ESBL-E. coli clones. Our review shows an increase in the number of publications between 2000 and 2019, concentrated mainly in Europe. Prevalence varied across continents, ranging from 0.63% (Oceania) to 16.56% (Africa) in dogs and from 0% (Oceania) to 16.82% (Asia) in cats. Although there were twice as many studies reporting prevalence on dogs (n = 61) than on cats (n = 32), and only 9 studies focused exclusively on cats, our meta-analysis showed no difference in the global prevalence of ESBL-E. coli between dogs (6.87% [95% CI: 4.46-10.45%]) and cats (5.04% [95% CI: 2.42-10.22%]). A considerable diversity of ESBL genes (n = 60) and sequence types (ST) (n = 171) were recovered from companion animals. ESBL-E. coli encoded by CTX-M-15 (67.5%, 77/114) and SHV-12 (21.9%, 25/114), along with resistant strains of ST38 (22.7%, 15/66) and ST131 (50%, 33/66) were widespread and detected in all continents. While presence of ESBL-E. coli is widespread, the drivers influencing the observed ESBL-E. coli prevalence and the clinical relevance in veterinary medicine and public health along with economic impact of ESBL-E. coli infections among companion animals need to be further investigated.

Keywords: Antimicrobial resistance; Companion animals; ESBL; Pets; Resistance genes; Worldwide.

© 2021 The Authors.

PubMed Disclaimer

Figures

Fig. 1

Fig. 1

Flow diagram of Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR).

Fig. 2

Fig. 2

Number of publications per continent over 2000–2020 period.

Fig. 3

Fig. 3

A: Number of publications of ESBL-E. coli in dogs and cats per country in gradient. B: Studies performed exclusively in dogs, or cats, or both per country.

Fig. 4

Fig. 4

Type of samples and proportion of specimens that were collected by included studies. Body fluids specimens includes effusions; Faecal specimens includes diarrhea and non-diarrhea; Gastrointestinal tract specimens includes digestive tract, enteritis, vomitus; Ocular specimens includes conjuntive, córnea, and eye; Others specimens referred as type of sample not specified; Respiratory tract [clinical] specimens includes bronchoalveolar lavage, sneeze, pharynx, pleural effusion, throat, and trachea lavage fluids; Respiratory tract [non-clinical] specimens includes nasal, and pharyngeal; Soft tissue/biopsy specimens includes colon, gut, liver, lung, and lymphonodes; Urogenital tract specimens includes uterus, vaginal secretion, intrauterine liquid, preputial secretion, prostate, pyometra, and scrotal fluid; Wounds/surgical sites specimens includes fistula.

Fig. 5

Fig. 5

Forest plot of the global prevalence of ESBL-E. coli in dogs and cats.

Fig. 6

Fig. 6

Forest plot of the prevalence of ESBL-E. coli in dogs across continent.

Fig. 7

Fig. 7

Forest plot of the prevalence of ESBL-E. coli in cats across continents.

Similar articles

Cited by

References

    1. WHO Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. 2017. https://www.who.int/medicines/publications/global-priority-list-antibiot...
    1. IACG No Time to Wait: Securing the future from drug-resistant infections, WHO. 2019. http://www.who.int/antimicrobial-resistance/interagency-coordination-gro...
    1. McGowan J.E., Jr. Economic impact of antimicrobial resistance. Emerg. Infect. Dis. 2001;7:286–292. doi: 10.3201/eid0702.010228. - DOI - PMC - PubMed
    1. O'Neill J. The Review on Antimicrobial Resistance - Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. 2016. https://amr-review.org/
    1. Joosten P., Ceccarelli D., Odent E., Sarrazin S., Graveland H., Van Gompel L., Battisti A., Caprioli A., Franco A., Wagenaar J.A., Mevius D., Dewulf J. Antimicrobial usage and resistance in companion animals: A cross-sectional study in three European Countries. Antibiotics. 2020;9 doi: 10.3390/antibiotics9020087. - DOI - PMC - PubMed

Publication types

LinkOut - more resources